Dr. Chandrasekharan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 Hawkins Drive
Iowa City, IA 52242Phone+1 319-356-2148Fax+1 904-244-3634
Education & Training
- Louisiana State University School of MedicineFellowship, Hematology and Medical Oncology, 2013 - 2016
- University of Florida College of Medicine JacksonvilleResidency, Internal Medicine, 2009 - 2012
- Kilpauk Medical CollegeClass of 2007
Certifications & Licensure
- IA State Medical License 2016 - 2026
- MN State Medical License 2012 - 2016
- LA State Medical License 2013 - 2015
- FL State Medical License Active through 2013
Clinical Trials
- Futibatinib in Patients With Specific FGFR Aberrations Start of enrollment: 2020 Aug 24
Publications & Presentations
PubMed
- 6 citationsTelotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea.Joseph S. Dillon, Chandrikha Chandrasekharan
Future Oncology. 2018-01-19 - 11 citationsBinimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.Faisal Shahjehan, Saivaishnavi Kamatham, Chandrikha Chandrasekharan, Pashtoon Murtaza Kasi
Drugs of Today. 2019-11-01 - 16 citationsOutcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma.Lionel A. Kankeu Fonkoua, Sakti Chakrabarti, Mohamad Bassam Sonbol, Pashtoon Murtaza Kasi, Jason S. Starr
International Journal of Cancer. 2021-07-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: